Initially the landmark statin trials proved the benefi t of using HMG CoA reductase inhibitors or "statins" in the hypercholesterolemic patient with heart disease. The Scandinavian Simvastatin Survival Study (4S) was such a secondary prevention study in which patients with angina or prior myocardial infarction with elevated cholesterol were randomized to receive either simvastatin or placebo and followed over a median of 5.4 years. There was a signifi cant reduction in MACE rates as well as a reduction in the need for further coronary revascularization. 
THE ORIGINAL OR LANDMARK STUDIES
Initially the landmark statin trials proved the benefi t of using HMG CoA reductase inhibitors or "statins" in the hypercholesterolemic patient with heart disease. The Scandinavian Simvastatin Survival Study (4S) was such a secondary prevention study in which patients with angina or prior myocardial infarction with elevated cholesterol were randomized to receive either simvastatin or placebo and followed over a median of 5.4 years. There was a signifi cant reduction in MACE rates as well as a reduction in the need for further coronary revascularization. (1) Following on the success of this secondary prevention trial, major primary prevention trials which examined the role of statins in hypercholesterolemic men without a prior history of myocardial infarction were reported. The West of Scotland Primary Prevention Study (WOSCOPS) demonstrated a 31% reduction in non-fatal myocardial infarction or coronary deaths, a 37% reduction in revascularization procedures and overall a 32% reduction in cardiovascular mortality. (2) The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study emphasized the importance of statins in secondary prevention by reducing mortality across a wide range of serum cholesterol levels (4-7 mmol/L) in long-term (mean 6.1 years) treatment.
The benefi t was mostly shown in patients with high cholesterol levels at baseline. (3) The Cholesterol and Recurrent Events (CARE) study published reductions in coronary events by 24% in patients with prior history of cardiovascular disease but with average cholesterol levels (5.4+/-0.4mmol/l). (4) Most of these trials failed to show reductions in non-cardiovascular events.
One of the largest statin trials to date, the Heart Protection Study (HPS) demonstrated signifi cant reductions in MACE, strokes and in revascularization procedures regardless of initial LDL levels. weeks follow-up. (7) This was a randomized, placebo-controlled trial and demonstrated a reduction in composite cardiovascular events by 16% (p=0.048) over the ensuing 4 months. Perhaps even more striking was the 50% reduction in stroke achieved in this study.
The Atorvastatin Versus Revascularization Treatment (AVERT) study compared aggressive atorvastatin therapy to coronary angioplasty.
Although risk reduction was not signifi cant after adjustment for interim analysis, the time to reach an ischemic event was signifi cantly longer in the atorvastatin group (RR 0.64, 0.33-0.95, p=0.03).
MORE AGGRESSIVE TREATMENT
Since higher doses of statins are able to lower lipid levels more signifi cantly, especially in the acute setting, questions arose as to whether high dose statin therapy, particularly with the use of the more potent statins, may lower event rates more than standard dose therapy.
In the Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction 22 (PROVE-IT) trial, patients were randomized to standard therapy or intensive therapy 10 days after an episode of acute coronary syndrome. (9) The primary end-point was the composite of death, myocardial infarction, hospitalized unstable angina, revascularization and stroke. At the end of two years, the primary end point rate was 26.3% with standard therapy and 22.4%
with intensive therapy. Progressively lower risk with progressively lower achieved LDL-cholesterol levels was achieved even in those patients with relatively low initial LDL-cholesterol levels.
A similar reduction in the composite primary end-point was observed in the A to Z trial. (10) This occurred more signifi cantly when early intensive therapy where high dose statin (simvastatin 80 mg daily) was initiated within 5 days of presenting with acute coronary syndrome than with delayed conservative therapy where lower dose statin was given 4 months after presentation.
In the Treating to New Targets (TNT) study, patients with stable coronary artery disease who achieved LDL levels after an 8-week runin period on low dose atorvastatin were randomized to either 10mg or 80mg atorvastatin daily. The mean LDL-cholesterol levels obtained were 2.6 mmol/l on the 10mg dose compared to 2.0 mmol/l on the 80mg dose of atorvastatin. A 22% reduction in cardiac events following a mean follow-up period of 5 years was seen with intensive therapy but overall mortality was not signifi cantly different. (11) In the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL), luminal stenosis measured on intravascular ultrasound was shown to be signifi cantly increased after 18 months in patients 30-75 years old with moderate lipid therapy compared with intensive therapy. (12) In the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) study, patients were randomized to either 20mg or 80mg of atorvastatin daily. (13) Patients selected were those with a prior history of myocardial infarction and most were therefore already on a statin. The primary endpoint of the trial was time to fi rst occurrence of coronary death, myocardial infarction or resuscitated cardiac arrest over a 5-year period. An 11% signifi cant reduction in the primary endpoint occurred with intensive therapy.
A meta-analysis of the A to Z, IDEAL, PROVE-IT and TNT studies compared intensive versus moderate statin therapy. (14) This showed a 16% (p<0.0001) reduction in coronary death or myocardial infarction, and an 18% reduction in stroke, (p=0.012), but little effect on cardiovascular death (P=0.73).
In composite, these randomized trials and meta-analyses indicate that benefi ts of statins are apparent within 4 months after acute coronary syndromes manifested, primarily as a reduction in recurrent unstable angina. Also, higher intensity statin treatment affords greater benefi t than lower intensity treatment in both early and later timeframes after acute coronary syndromes.
STATIN THERAPY IN ACS

THE SAFETY OF STATINS
With such successful results garnering in an era of widespread statin use and evidence of more benefi cial effects with higher doses, safety concerns undoubtedly develop. Cholesterol is a core component of cellular membranes and lowering levels intensively could interfere with normal regenerative processes. Ophthalmopathy and encephalopathy occurred in early studies with dogs on very high doses. However, this
has not been demonstrated to occur in man.
Statins are remarkably safe and well-tolerated drugs. (15, 16) Even at high doses the major adverse effects of the statins, namely myopathy and raised liver enzymes, are uncommon. The risk of rhabdomyolysis is < 4 per 100 000 patient years.
The normal LDL-cholesterol range is 1 -1.8 mmol/l in healthy neonates, hunter-gatherers and free living primates. 
Statin therapy should now be considered routine in all patients following an acute coronary event. Follow-up testing of LDL cholesterol levels should be mandatory to monitor effectiveness of individual drug use and assess adherence to therapy and dietary advice. However, in South Africa, as in most countries, despite the documented benefi t of early intensive statin therapy post an acute coronary event, there appears to be a reluctance to prescribe statin therapy, particularly high-dose statin therapy. All physicians should try to adhere to the latest South African
Lipid guidelines, which have been adopted from the European guidelines and should be encouraged to prescribe these remarkable drugs in patients at high risk or with documented cardiovascular disease. (19) They should strive to achieve the LDL-cholesterol goal of < 2. African setting is paramount.
